Market Cap 327.45M
Revenue (ttm) 210.78M
Net Income (ttm) 65.63M
EPS (ttm) N/A
PE Ratio 4.26
Forward PE N/A
Profit Margin 31.14%
Debt to Equity Ratio 0.00
Volume 155,900
Avg Vol 142,400
Day's Range N/A - N/A
Shares Out 37.60M
Stochastic %K 69%
Beta 0.04
Analysts Strong Sell
Price Target $24.33

Latest News on TRDA

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19, 2025, 11:31 AM EST - 2 months ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside


Entrada Therapeutics: Early Stage But Interesting

Aug 3, 2023, 6:39 PM EDT - 1 year ago

Entrada Therapeutics: Early Stage But Interesting


Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex